Steinar Madsen, MD, medical director of the Norwegian Medicines Agency, shared lessons learned from the Norwegian experience with biosimilars in a Wednesday talk at the SMi Biosimilars North America conference.
Steinar Madsen, MD, medical director of the Norwegian Medicines Agency (NMA), shared lessons learned from the Norwegian experience with biosimilars in a Wednesday talk at the SMi Biosimilars North America conference.
Madsen opened his session by saying that, as a physician, “the most important thing is that I can treat all of my patients,” and noting that biosimilars have allowed for significantly increased access to biologics—especially anti—tumor necrosis factor agents—in Norway. “We start with the biological in an earlier stage than we previously did,” said Madsen, and added that “today, patients with [rheumatoid arthritis] get much better treatment than they did 10 years ago. That’s absolutely certain.”
Norway, which recommends switching to biosimilars—and provides strong financial incentives to health systems that switch to biosimilars—has been hailed as a model for the rest of the world. Yet prescriber acceptance and adoption of biosimilar therapies did not happen overnight. “I’ve been doing myth-busting,” Madsen said. “The most important myth is that the reference product is the gold standard. This was repeated to doctors again and again,” and physicians “were considerably influenced by the anti-biosimilar campaign.”
However, physician education, said Madsen, has ensured that Norwegian physicians are now widely aware of the batch-to-batch variability with biologics, and that biosimilars are non-inferior to their references. Patients, too, he said, have become less skeptical of these therapies as they see more patients gaining access to high-quality treatments.
Madsen had words of advice for US healthcare stakeholders—to whom he said, “You have the worst healthcare system in the world if you look at how much you spend on it,”—on the following topics:
Interchangeable Status
In Madsen’s view, the US emphasis on interchangeability of biosimilars with their reference products is unwarranted. The NMA’s official opposition on switching among products is that it is not only safe to switch from a reference product to a biosimilar, but that it is also safe to switch among biosimilars of the same reference. Further clinical studies on the matter, he said, are unnecessary.
Pharmacovigilance
The Norwegian approach to pharmacovigilance for biosimilars also stands in contrast to FDA policies. The FDA requires a 4-letter suffix, devoid of meaning, to be appended to the names of biosimilars in order to track any adverse events related to individual biosimilars. By contrast, Norwegian regulators have devised a soon-to-be-implemented system in which specific batches of products will be correlated with any adverse events or anti-drug antibodies using a unique number assigned to patient packages of drugs. These numbers will be automatically transmitted to patient’s health records when the biologics are dispensed to patients.
Pricing and Competition
Finally, Madsen told US biosimilar developers that, when determining how to price their products against reference products, “the magic [number] is 40%.” This discount, he indicated, is sufficiently aggressive to spur meaningful price competition.
However, because the US market stands in contrast to Norway’s tender system, where there is “no wheeling and dealing, no kickbacks,” Madsen added that the United States should implement restrictions on retroactive price-matching and the bundling of products to help preserve true competition in the market.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.